Back to top
more

Acasti Pharma (ACST)

(Delayed Data from NSDQ)

$2.73 USD

2.73
32,608

+0.16 (6.02%)

Updated Sep 17, 2024 03:40 PM ET

After-Market: $2.78 +0.05 (1.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (37 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Acasti Pharma, Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 23 28 44 61 14
Receivables 1 1 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 0 1 1 1 1
Total Current Assets 24 29 46 62 16
Net Property & Equipment 0 0 0 0 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 49 49 83 0 4
Deposits & Other Assets 0 0 0 0 0
Total Assets 73 79 129 62 23
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 2 3 3 1 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 2 3 3 2 7
Mortgages 0 0 0 0 0
Deferred Taxes/Income 6 7 17 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4 0 0 5 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 12 11 20 7 10
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 261 258 258 197 137
Capital Surplus 18 14 12 11 10
Retained Earnings -211 -198 -156 -146 -126
Other Equity -6 -6 -6 -6 -8
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 62 68 108 56 13
Total Liabilities & Shareholder's Equity 73 79 129 62 23
Total Common Equity 62 68 108 56 13
Shares Outstanding 9.40 7.40 7.30 4.30 1.80
Book Value Per Share 6.57 9.18 14.83 12.94 7.22

Fiscal Year End for Acasti Pharma, Inc falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 19 23 25 27 22
Receivables 0 1 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 1 0 1 1 1
Total Current Assets 20 24 27 29 24
Net Property & Equipment 0 0 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 49 49 49 49 49
Deposits & Other Assets 0 0 0 0 0
Total Assets 70 73 76 78 73
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 2 2 1 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 3 2 2 1 2
Mortgages 0 0 0 0 0
Deferred Taxes/Income 5 6 6 7 7
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 3 3 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 10 12 12 11 9
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 261 261 261 261 258
Capital Surplus 18 18 18 17 14
Retained Earnings -214 -211 -208 -206 -202
Other Equity -6 -6 -6 -6 -6
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 59 62 65 67 64
Total Liabilities & Shareholder's Equity 70 73 76 78 73
Total Common Equity 59 62 65 67 64
Shares Outstanding 10.10 9.40 9.40 7.40 7.40
Book Value Per Share 5.88 6.57 6.88 9.02 8.65